Agilent to acquire Resolution Bioscience for $695 M
Agilent to acquire Resolution Bioscience for $695 M
03 March 2021 | News
Source credit: Shutterstock
Agilent Technologies Inc has announced that it has entered into a definitive agreement to acquire Resolution Bioscience Inc, a leader in the development and commercialisation of next-generation sequencing (NGS)-based precision oncology solutions.
The acquisition complements and expands Agilent’s capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further serve the needs of the fast-growing precision medicine market.
Under the terms of the agreement, Agilent will pay $550 million in cash at closing and up to an additional $145 million based on achieving future performance milestones.